Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Status:
Open
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
NCT#04671667
EA3191 is reopened to accrual with the implementation of Addendum 6, effective April 18, 2023
